2-D and 3-D patient-derived models
ATCC is excited to provide the HCMI models, which include both common as well as rare and understudied examples of cancer from numerous tissues. These HCMI models are valuable tools to study cancer, identify and target novel therapies, and facilitate translational cancer research. To enhance their clinical relevance, the sequence data and patient clinical information for each model is available to the research community.
Why choose ATCC patient-derived models for your drug development?
- All models are derived from human cancer patients
- Diverse genetic backgrounds
- Advanced models such as organoids
- Clinical and sequencing data available via the HCMI portal
- Models from primary, metastatic, and recurrent cancer
- Rare and pediatric cancers included
- Model-specific, easy-to-follow culturing protocols
- Growth kits available for streamlined media preparation
What is HCMI? Explore HCMI cancer models Example data Organoid culture guide
Organoid culture guide
ATCC scientists created educational materials that contains everything you need to know about the initiation, expansion, and cryopreservation of organoids in embedded 3-D culture.
HCMI searchable catalog
Search HCMI models by patient demographics, tumor, and model elements including diagnosis age, sex, treatment information, clinical tumor diagnosis, primary site, clinical stage, model type, and open-access masked somatic MAF variants, etc.
What is the Human Cancer Models Initiative (HCMI)?
The Human Cancer Models Initiative (HCMI) is an international consortium that is dedicated to generating novel human tumor-derived culture models with associated genomic and clinical data. The HCMI consortium comprises funding agencies and cancer model development institutions.
- Funding Agencies: National Cancer Institute (NCI), Cancer Research UK (CRUK), Hubrecht Organoid Technology (HUB), and Wellcome Sanger Institute (WSI).
- NCI-funded model development institutions: Broad Institute and the Cold Spring Harbor Laboratory.
- Sole Distributor: ATCC (authenticates, expands, preserves, and distributes models globally)
- The HCMI model data are available from the NCI as a resource to the research community.
Evaluating the mechanism of action of MRTX1133 as a selective KRAS-G12D inhibitor. (A) The allelic discrimination plots confirm KRAS-G12D and KRAS-G12V mutation in selected CCOs. (B) KRAS-G12D mutated CCOs (PDM-43™ and PDM-419™) are more sensitive to MRTX1133.
